Table 1.
Patient Characteristics
| Cohort 1 N=44 |
Cohort 2 N=26 |
Total N=70 |
|
|---|---|---|---|
| Males (%) | 27 (61%) | 15 (58%) | 42 (60%) |
| Age at onset of KD, yrs: 1st quartile, median, 3rd quartile | 1.2, 2.4, 5.9 | 3.0, 4.5, 7.5 | 1.4, 3.4, 6.5 |
| Age at time of CT, yrs: 1st quartile, median, 3rd quartile | 13.4, 16.7, 20.5 | 21.6, 27.7, 32.4 | 14.7, 20.0, 24.8 |
| Interval from onset of KD to CT scan, years: 1st quartile, median, 3rd quartile | 10.5, 13.4, 16.0 | 13.0, 24.5, 28.3 | 10.9, 14.8, 23.8 |
| Coronary artery status | |||
| No dilation | 26 (59%) | 18 (69%) | 44 (63%) |
| Transiently dilated | 11 (25%) | 1 (4%) | 12 (17%) |
| Aneurysm < 8mm in diameter | 5 (11%) | 3 (12%) | 8 (11%) |
| Giant aneurysm (≥ 8mm in diameter) | 2 (5%) | 4 (15%) | 6 (9%) |
| Cardiovascular Risk Factors | |||
| Hypertension | 2 (5%) | 2 (8%) | 4 (6%) |
| Diabetes Mellitus | 1 (2%) | 1 (4%) | 3 (4%) |
| Current Smoking | 3 (7%) | 2 (8%) | 5 (7%) |
| Hyperlipidemia | 5 (11%) | 6 (23%) | 11 (16%) |
| Family History of Early CAD (< 55 yrs) | 14 (32%) | 11 (42%) | 25 (36%) |
| Body Mass Index (kg/m2): 1st quartile, median, 3rd quartile | 19, 21, 24 | 20, 22, 24 | 19, 22, 24 |
| Medications | |||
| Statin medication | 2 (5%) | 3 (12%) | 5 (7%) |
| Niacin | 1 (2%) | 1 (4%) | 2 (3%) |
| ACE-I or ARB | 3 (7%) | 3 (12%) | 6 (9%) |
| Beta blocker | 2 (5%) | 2 (12%) | 5 (7%) |
| Calcium channel blocker | 2 (5%) | 0 (0%) | 2 (3%) |
| Warfarin or Dabigatran | 3 (7%) | 3 (12%) | 6 (9%) |
| Aspirin | 5 (11%) | 10 (38%) | 15 (21%) |
| Clopidogrel | 2 (5%) | 2 (8%) | 4 (6%) |
Key: Cohort 1: Patients originally diagnosed, treated, and followed by the Kawasaki Disease Research Center at the University of California, San Diego Medical Center and Rady Children’s Hospital
Cohort 2: All other patients
ACE-I: Angiotensin-converting enzyme inhibitors
ARB: Angiotensin II receptor blockers